Financial Performance - Total revenue for Q1 2025 reached ¥55,628,550.27, representing a 53.95% increase compared to ¥36,133,021.41 in Q1 2024[9] - Net profit attributable to shareholders was ¥3,360,866.95, a significant increase of 287.30% from ¥867,778.34 in the same period last year[9] - Operating profit for Q1 2025 was ¥3,711,434.11, a substantial rise from ¥380,534.86 in Q1 2024, reflecting a growth of over 875%[39] - Net profit for Q1 2025 reached ¥4,143,440.08, compared to ¥300,297.81 in Q1 2024, marking an increase of approximately 1,276%[39] - The company's net profit for Q1 2025 reached CNY 8,912,764.19, a significant increase from CNY 2,261,665.67 in Q1 2024, representing a growth of approximately 293%[43] - The company reported a total comprehensive income of CNY 8,912,764.19 for Q1 2025, compared to CNY 2,261,665.67 in Q1 2024, marking a substantial increase[43] Cash Flow and Liquidity - The company's net cash flow from operating activities was -¥7,486,192.20, a decline of 228.28% compared to ¥5,835,664.45 in Q1 2024[9] - Cash and cash equivalents increased by 43.12% to ¥83,253,648.47, mainly due to the redemption of financial products during the reporting period[10] - Cash generated from operating activities in Q1 2025 was CNY 53,998,295.87, compared to CNY 34,589,226.48 in Q1 2024, showing an increase of approximately 56.4%[45] - Operating cash inflow totaled CNY 62,260,933.70, an increase from CNY 39,287,452.69 year-over-year[46] - Operating cash outflow amounted to CNY 69,747,125.90, compared to CNY 33,451,788.24 in the previous year[46] - The net increase in cash and cash equivalents was CNY 26,567,367.65, compared to CNY 16,059,008.07 in the previous year[47] Assets and Liabilities - The total assets as of March 31, 2025, were ¥458,239,347.43, a decrease of 2.98% from ¥472,303,260.29 at the end of 2024[9] - Total liabilities as of March 31, 2025, were ¥85,338,233.51, down from ¥105,449,554.47 at the end of 2024, indicating a reduction of about 19%[37] - Shareholders' equity totaled ¥384,938,114.92 as of March 31, 2025, compared to ¥376,025,350.73 at the end of 2024, showing an increase of approximately 2.3%[37] - The total current liabilities decreased from 106,958,989.22 CNY on December 31, 2024, to 91,132,488.96 CNY on March 31, 2025[32] Shareholder Information - The total number of ordinary shares is 97,686,643, with 56.60% being unrestricted shares held by controlling shareholders[16] - Wang Min holds 25,385,114 shares, representing 25.99% of total shares, while Wang Fang holds 19,032,636 shares, representing 19.48%[18] - The top ten shareholders collectively hold 67,407,173 shares, accounting for 69.00% of total shares[18] - The total number of ordinary shareholders is 4,764[16] Stock Incentive Plan - The company has implemented a stock incentive plan, granting 675,000 restricted shares and 805,000 stock options to 58 individuals, including directors and core employees[22] - The exercise price for stock options was adjusted from 22.50 CNY to 22.30 CNY due to equity distribution[23] - The company approved the release of 181,800 restricted stocks from the 2022 equity incentive plan on May 23, 2023[24] - A total of 62,700 restricted stocks and 137,000 stock options were canceled due to underperformance and employee departures[24] - The number of stock options granted in the 2022 equity incentive plan was adjusted from 745,000 to 1,484,649, with the exercise price reduced from 22.30 CNY to 11.09 CNY[25] - As of March 31, 2025, a total of 675,000 restricted stocks and 945,000 stock options were granted under the 2022 equity incentive plan, with 181,800 restricted stocks released from restrictions[27] Operational Metrics - The gross profit margin for the period improved significantly, with operating profit reaching ¥3,711,434.11, an increase of 875.32% year-on-year[11] - The company reported a 74.89% increase in operating costs, totaling ¥32,447,719.61, primarily due to increased revenue[11] - Total operating costs for Q1 2025 were ¥53,097,320.57, compared to ¥36,784,965.80 in Q1 2024, indicating an increase of about 44%[39] - Research and development expenses for Q1 2025 were CNY 4,525,853.45, slightly down from CNY 5,028,609.51 in Q1 2024, indicating a focus on cost management[42] Other Information - The company has not reported any litigation, arbitration, or external guarantees during the reporting period[21] - There are no pledged or frozen shares among the top shareholders[19] - The company has not engaged in any significant asset acquisitions or mergers during the reporting period[21] - The company experienced a decrease in minority shareholders' comprehensive income, which was CNY -57,398.36 in Q1 2025, compared to CNY -635,687.78 in Q1 2024[41] - The total other comprehensive income after tax for Q1 2025 was CNY -26,270.42, compared to CNY -10,025.48 in Q1 2024, indicating a decline[43] - The company reported a net investment loss of CNY -23,401.03 in Q1 2025, compared to CNY -10,820.90 in Q1 2024, reflecting challenges in investment performance[42]
锦好医疗(872925) - 2025 Q1 - 季度财报